Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quantum Genomics, a biotechnology company, has received a research financing worth $1 million from the French agency Oseo, to perform a preclinical evaluation of QGC 001, the first drug to treat hypertension by targeting Aminopeptidase A. The company has initiated the preclinical studies required for the submission of an investigational medicinal product dossier.
Subscribe to our email newsletter
First good manufacturing practice (GMP) batch of the drug substance has been released and 12kg are available to perform all the toxicological and safety studies and to initiate early clinical trials in human subjects, the company said.
Lionel Segard, CEO of Quantum Genomics, said: “The support of Oseo for the development of QGC 001 is exciting reinforcement of the high potential of this first in class drug.”